Virbac SA
Healthcare · EUR · EPA
Price
€360.5
Cap
€2.93B
Earnings
—
30d Trend
-3.5%
26% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 48×Macro 0.99 (−1%)=48
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
3-6 month opportunity — emerging trend
BRAIN47'S ASSESSMENT
I rate Virbac SA at 48/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 61/100. I classify this as a growth position with the strongest thesis on a medium-term horizon.
PAST PERFORMANCE
1 MONTH
-0.7%
3 MONTHS
-1.8%
12 MONTHS
+13.0%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
3-6 month opportunity — emerging trend. Momentum (61) and low-risk profile are the primary strengths. I note that quality is the weakest area at 28/100 — this warrants monitoring. Historical volatility is moderate at 26%. I classify this as a growth position — positive trend direction combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.